High dose methotrexate with and without BCG therapy in advanced head and neck malignancy

Twenty‐three patients with advanced recurrent head and neck carcinoma were randomized to receive either high dose methotrexate with calcium leucovorin rescue (HDMTX) or HDMTX in combination with bacilli Calmette Guerin (HDMTX/BCG). An additional eight patients were treated with escalating doses of HDMTX ranging from 1 to 7 g of methotrexate. Of 12 patients receiving HDMTX, one complete response and two partial responses were noted. Of 11 patients in the HDMTX/BCG group, one complete response and two partial responses were observed. Only one partial response was noted in eight patients receiving escalating doses of the drug. Responses were brief and no significant difference in response duration was seen in any particular group. Toxicities in all groups were tolerable. BCG did not improve response rate, median duration of response, or median survival in these patients. Reported experiences with high dose methotrexate have been reviewed and again, responses to “high dose methotrexate” were found to be of brief duration. Despite acceptable toxicity, the brief duration of response and cost of such therapy raises serious question on the usefulness of chemoimmunotherapy utilizing high dose methotrexate with leucovorin rescue and BCG in the management of advanced recurrent carcinomas of the head and neck region. Cancer 43:1095–1100, 1979.

[1]  J. Bertino "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. , 1977, Seminars in oncology.

[2]  J. Sullivan,et al.  HIGH‐DOSE METHOTREXATE THERAPY , 1977, The Medical journal of Australia.

[3]  A. Ketcham,et al.  High dose methotrexate as a preoperative adjuvant in the treatment of epidermoid carcinoma of the head and neck. A feasibility study and clinical trial. , 1975, American journal of surgery.

[4]  R. Donaldson Chemoimmunotherapy for cancer of the head and neck. , 1973, American journal of surgery.

[5]  J. Bertino,et al.  Improved therapeutic index of methotrexate with "leucovorin rescue". , 1973, Cancer research.

[6]  R. Donaldson Methotrexate plus Bacillus Calmette-Guérin (BCG) and isoniazid in the treatment of cancer of the head and neck. , 1972, American journal of surgery.

[7]  M. Friedman,et al.  Treatment of squamous cell carcinoma of the head and neck with combined methotrexate and irradiation , 1970, Cancer.

[8]  J. Bertino,et al.  Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue". , 1970, Cancer research.

[9]  J. Bertino,et al.  Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck. , 1968, Cancer research.

[10]  J. Bertino,et al.  Head and neck cancer. 3. Toxicity of 24-hour infusions of methotrexate (NSC-740) and protection by leucovorin (NSC-3590) in patients with epidermoid carcinomas. , 1967, Cancer chemotherapy reports.

[11]  N. Mantel,et al.  Eradication Of Leukaemic Cells (L1210) by Methotrexate and Methotrexate Plus Citrovorum Factor , 1966, Nature.